[New central agents in the treatment of arterial hypertension].
Robles
N R
NR
D018759:Adrenergic Uptake Inhibitors / Q000627:therapeutic use; D000316:Adrenergic alpha-Agonists / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000328:Adult; D000959:Antihypertensive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001262:Atenolol / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D003000:Clonidine / Q000627:therapeutic use; D048909:Diabetes Complications; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D007093:Imidazoles / Q000627:therapeutic use; D009543:Nifedipine / Q000627:therapeutic use; D010080:Oxazoles / Q000627:therapeutic use; D012084:Renin-Angiotensin System / Q000187:drug effects / Q000502:physiology; D012110:Reserpine / Q000627:therapeutic use; D000077769:Rilmenidine; D012307:Risk Factors; D013564:Sympathetic Nervous System / Q000187:drug effects / Q000503:physiopathology; D014665:Vasodilator Agents / Q000627:therapeutic use
D018759:Adrenergic Uptake Inhibitors; D000316:Adrenergic alpha-Agonists; D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D007093:Imidazoles; D010080:Oxazoles; D014665:Vasodilator Agents; D001262:Atenolol; D012110:Reserpine; C043482:moxonidine; D009543:Nifedipine; D003000:Clonidine; D000077769:Rilmenidine
Nuevos agentes centrales en el tratamiento de la hipertensión arterial.